The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy

Cancer Immunology, Immunotherapy

Volumn 59, Issue 2, 2010, Pages 279-291

  Wu, Xia ^a   Feng, Qin Mei ^a   Wang, Ying ^b   Shi, Jun ^a   Ge, Hai Liang ^b   Di, Wen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Chemotherapy; Immune reconstitution; Immunogenicity; Ovarian cancer

Indexed keywords

B7 ANTIGEN; CARBOPLATIN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; PACLITAXEL; TUMOR ANTIGEN;

ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NATURAL KILLER T CELL; OVARY CANCER; PHAGOCYTOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TREATMENT DURATION; TUMOR IMMUNITY;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 71849088755     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0749-9     Document Type: Article

References (41)

1. A Jemal R Siegel E Ward T Murray J Xu C Smigal MJ Thun 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130 10.3322/canjclin.56.2.106 16514137
2. CH Holschneider JS Berek 2000 Ovarian cancer: epidemiology, biology, and prognostic factors Semin Surg Oncol 19 3 10 10.1002/1098-2388(200007/08)19: 1<3::AID-SSU2>3.0.CO;2-S 1:STN:280:DC%2BD3cvgslehsg%3D%3D 10883018 (Pubitemid 30439309)
3. L Zitvogel L Apetoh F Ghiringhelli G Kroemer 2008 Immunological aspects of cancer chemotherapy Nat Rev Immunol 8 59 73 10.1038/nri2216 1:CAS:528:DC%2BD2sXhsVKrsLnP 18097448
4. HL Weiner JA Cohen 2002 Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects Mult Scler 8 142 154 10.1191/1352458502ms790oa 1:CAS:528:DC%2BD38Xjt1Chs7c%3D 11990872 (Pubitemid 34256752)
5. ME Weinblatt JS Coblyn DA Fox PA Fraser DE Holdsworth DN Glass DE Trentham 1985 Efficacy of low-dose methotrexate in rheumatoid arthritis N Engl J Med 312 818 822 1:STN:280:DyaL2M7jslOmtw%3D%3D 3883172
6. OT Chan LX Yang 2000 The immunological effects of taxanes Cancer Immunol Immunother 49 181 185 10.1007/s002620000122 1:CAS:528:DC%2BD3cXlvFymsb8%3D 10941900
7. M Skoberne AS Beignon M Larsson N Bhardwaj 2005 Apoptotic cells at the crossroads of tolerance and immunity Curr Top Microbiol Immunol 289 259 292 10.1007/3-540-27320-4-12 1:CAS:528:DC%2BD2MXktlertbY%3D 15791960
8. FH Igney PH Krammer 2002 Death and anti-death: tumour resistance to apoptosis Nat Rev Cancer 2 277 288 10.1038/nrc776 1:CAS:528:DC%2BD38XivFGqt7s%3D 12001989
9. CO Bellamy RD Malcomson DJ Harrison AH Wyllie 1995 Cell death in health and disease: the biology and regulation of apoptosis Semin Cancer Biol 6 3 16 10.1006/scbi.1995.0002 1:STN:280:DyaK28%2FjslOksw%3D%3D 7548839
10. M Obeid A Tesniere F Ghiringhelli GM Fimia L Apetoh JL Perfettini M Castedo G Mignot T Panaretakis N Casares D Metivier N Larochette P van Endert F Ciccosanti M Piacentini L Zitvogel G Kroemer 2007 Calreticulin exposure dictates the immunogenicity of cancer cell death Nat Med 13 54 61 10.1038/nm1523 1:CAS:528:DC%2BD2sXhvFWisw%3D%3D 17187072 (Pubitemid 46067386)
11. N Chaput S De Botton M Obeid L Apetoh F Ghiringhelli T Panaretakis C Flament L Zitvogel G Kroemer 2007 Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference J Mol Med 85 1069 1076 10.1007/s00109-007-0214-1 1:CAS:528:DC%2BD2sXhtVOit7%2FE 17891368 (Pubitemid 47476729)
12. C Menard F Martin L Apetoh F Bouyer F Ghiringhelli 2008 Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity Cancer Immunol Immunother 57 1579 1587 10.1007/s00262-008- 0505-6 1:CAS:528:DC%2BD1cXhtVejsbbE 18369619
13. MB Flick D O'Malley T Rutherford S Rodov M Kamsteeg XY Hao P Schwartz BM Kacinski G Mor 2004 Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients J Soc Gynecol Investig 11 252 259 10.1016/j.jsgi.2003.11.003 1:CAS:528:DC%2BD2cXjs1WksLo%3D 15120700 (Pubitemid 38561371)
14. O Boisteau F Gautier S Cordel F Henry J Harb JY Douillard FM Vallette K Meflah M Gregoire 1997 Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line Apoptosis 2 403 412 10.1023/A:1026461825570 1:CAS:528:DyaK2sXms12ltrs%3D 14646537
15. F Henry O Boisteau L Bretaudeau B Lieubeau K Meflah M Gregoire 1999 Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines Cancer Res 59 3329 3332 1:CAS:528:DyaK1MXks1Omsrg%3D 10416588
16. N Romani S Gruner D Brang E Kampgen A Lenz B Trockenbacher G Konwalinka PO Fritsch RM Steinman G Schuler 1994 Proliferating dendritic cell progenitors in human blood J Exp Med 180 83 93 10.1084/jem.180.1.83 1:CAS:528: DyaK2cXkvVSrurw%3D 8006603 (Pubitemid 24181058)
17. P Mulders CL Tso B Gitlitz R Kaboo A Hinkel S Frand S Kiertscher MD Roth J deKernion R Figlin A Belldegrun 1999 Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines Clin Cancer Res 5 445 454 1:CAS:528:DyaK1MXhsVWrtLc%3D 10037196
18. RM Steinman I Mellman 2004 Immunotherapy: bewitched, bothered, and bewildered no more Science 305 197 200 10.1126/science.1099688 1:CAS:528:DC%2BD2cXlsV2gtr8%3D 15247468 (Pubitemid 38886724)
19. L Zitvogel A Tesniere G Kroemer 2006 Cancer despite immunosurveillance: immunoselection and immunosubversion Nat Rev Immunol 6 715 727 10.1038/nri1936 1:CAS:528:DC%2BD28XhtVSgurnM 16977338 (Pubitemid 44453458)
20. RA Lake RG van der Most 2006 A better way for a cancer cell to die N Engl J Med 354 2503 2504 10.1056/NEJMcibr061443 1:CAS:528:DC%2BD28XlsVags7Y%3D 16760453 (Pubitemid 43855057)
21. N Casares MO Pequignot A Tesniere F Ghiringhelli S Roux N Chaput E Schmitt A Hamai S Hervas-Stubbs M Obeid F Coutant D Metivier E Pichard P Aucouturier G Pierron C Garrido L Zitvogel G Kroemer 2005 Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J Exp Med 202 1691 1701 10.1084/jem.20050915 1:CAS:528:DC%2BD2MXhtlCjsrjK 16365148 (Pubitemid 41815875)
22. M Obeid T Panaretakis A Tesniere N Joza R Tufi L Apetoh F Ghiringhelli L Zitvogel G Kroemer 2007 Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic Cancer Res 67 7941 7944 10.1158/0008-5472.CAN- 07-1622 1:CAS:528:DC%2BD2sXpvFKjtrw%3D 17804698 (Pubitemid 47395121)
23. M Schnurr C Scholz S Rothenfusser P Galambos M Dauer J Robe S Endres A Eigler 2002 Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells Cancer Res 62 2347 2352 1:CAS:528:DC%2BD38Xjt1ejur0%3D 11956095
24. TK Hoffmann N Meidenbauer G Dworacki H Kanaya TL Whiteside 2000 Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells Cancer Res 60 3542 3549 1:CAS:528:DC%2BD3cXkvFChsLY%3D 10910067
25. K Inaba S Turley F Yamaide T Iyoda K Mahnke M Inaba M Pack M Subklewe B Sauter D Sheff M Albert N Bhardwaj I Mellman RM Steinman 1998 Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells J Exp Med 188 2163 2173 10.1084/jem.188.11.2163 1:CAS:528:DyaK1cXnvFOgsr4%3D 9841929 (Pubitemid 28562532)
26. ML Albert B Sauter N Bhardwaj 1998 Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs Nature 392 86 89 10.1038/32183 1:CAS:528:DyaK1cXhvVOntrw%3D 9510252 (Pubitemid 28150594)
27. ML Albert SF Pearce LM Francisco B Sauter P Roy RL Silverstein N Bhardwaj 1998 Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes J Exp Med 188 1359 1368 10.1084/jem.188.7.1359 1:CAS:528:DyaK1cXmsFals78%3D 9763615 (Pubitemid 28478024)
28. RG van der Most AJ Currie BW Robinson RA Lake 2008 Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all Cell Death Differ 15 13 20 10.1038/sj.cdd.4402255 18007666 (Pubitemid 350286168)
29. RJ Binder PK Srivastava 2005 Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells Nat Immunol 6 593 599 10.1038/ni1201 1:CAS:528:DC%2BD2MXktlWitrc%3D 15864309 (Pubitemid 41710730)
30. N Ito H Nakamura Y Tanaka S Ohgi 1999 Lung carcinoma: analysis of T-helper type 1 and 2 cells and T-cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry Cancer 85 2359 2367 10.1002/(SICI)1097- 0142(19990601)85:11<2359::AID-CNCR10>3.0.CO;2-A 1:STN:280: DyaK1M3osVaqug%3D%3D 10357406 (Pubitemid 29244844)
31. BC Sheu RH Lin HC Lien HN Ho SM Hsu SC Huang 2001 Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer J Immunol 167 2972 2978 1:CAS:528:DC%2BD3MXmtlSju7o%3D 11509647
32. RA Kemp F Ronchese 2001 Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity J Immunol 167 6497 6502 1:CAS:528: DC%2BD3MXovVCitLY%3D 11714817
33. EJ Wherry DL Barber SM Kaech JN Blattman R Ahmed 2004 Antigen-independent memory CD8 T cells do not develop during chronic viral infection Proc Natl Acad Sci USA 101 16004 16009 10.1073/pnas.0407192101 1:CAS:528:DC%2BD2cXhtVGis7%2FM 15505208 (Pubitemid 39507917)
34. SM Kaech JT Tan EJ Wherry BT Konieczny CD Surh R Ahmed 2003 Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells Nat Immunol 4 1191 1198 10.1038/ni1009 1:CAS:528:DC%2BD3sXpt1Snt78%3D 14625547 (Pubitemid 37540688)
35. RH Schabowsky S Madireddi R Sharma ES Yolcu H Shirwan 2007 Targeting CD4+CD25+FoxP3+ regulatory T cells for the augmentation of cancer immunotherapy Curr Opin Investig Drugs 8 1002 1008 1:CAS:528:DC%2BD1cXpslGktw%3D%3D 18058571
36. + regulatory T-cell proliferation J Exp Med 202 919 929 10.1084/jem.20050463 1:CAS:528:DC%2BD2MXhtVygt73F 16186184 (Pubitemid 41396892)
37. S Brode A Cooke 2008 Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide Crit Rev Immunol 28 109 126 1:CAS:528:DC%2BD1cXmtFKhs7c%3D 18540827
38. + regulatory T cells and restores T and NK effector functions in end-stage cancer patients Cancer Immunol Immunother 56 641 648 10.1007/s00262-006-0225-8 1:CAS:528:DC%2BD2sXisVaqtbY%3D 16960692 (Pubitemid 46348738)
39. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative Eur J Immunol 34 336 344 10.1002/eji.200324181 1:CAS:528:DC%2BD2cXhsFals7k%3D 14768038 (Pubitemid 39255944)
40. AK Nowak RA Lake AL Marzo B Scott WR Heath EJ Collins JA Frelinger BW Robinson 2003 Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells J Immunol 170 4905 4913 1:CAS:528: DC%2BD3sXjsVGqsro%3D 12734333
41. + T-cell function during systemic chemotherapy in advanced ovarian cancer Cancer Res 65 7000 7006 10.1158/0008-5472.CAN-04-3792 1:CAS:528:DC%2BD2MXmvFSlu7o%3D 16061686 (Pubitemid 41060740)